When will Beam Therapeutics Inc. submit a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA?
Prediction markets currently give a 64% probability that When will Beam Therapeutics Inc. submit a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA?. This contract trades at 64¢ on Kalshi, closing January 1, 2027. This market shows zero liquidity with no 24-hour volume and zero open interest, making the 0¢ price unreliable as a probability signal.
Analysis
This market shows zero liquidity with no 24-hour volume and zero open interest, making the 0¢ price unreliable as a probability signal. The extreme implied yields (97.7% for Yes, 202.3% for No) reflect the illiquidity rather than genuine market conviction, and the 10¢ spread is unusually wide for a binary contract. With 260 days to expiry and minimal trading activity, this market lacks sufficient depth to provide actionable insights on Beam's BLA submission timeline for risto-cel.
Resolution rules
If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Jan 1, 2027, then the market resolves to Yes.
Indicators
Regime
Trade
sf trade KXNEWDRUGAPPBEAM-RIST-27JAN01 yes 100